2Mochizuki S, Shimizu M, Taniguchi I, et al. JIKEIHEART Study-amorbimortality and remodeling study with valsartanin Japanese patients with hypertension and cardiovascular disease [J].Cardiovasc Drugs Tner,2004, 18:305-309.
3The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [J].JAMA,2002,288: 2981.
4Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J]. Lancet, 2004,363:2022-2031.
5Dahlof B, Sever PS, Pouher NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a muhicentre randomised controlled trial[J].Lancet, 2005,366:895-906.
6[1]清溪.血压达标的重要性和ARB的新作用[N].中国医学论坛报,2006-9-28(36).
7[3]Mochizuki S,Shimizu M,Taniguchi I,et al.JIKEI HEART Study-a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease[J].Cardiovasc Drugs Ther,2004,18:305-309.
8秦玉珍 王昌河.老年病高血压的治疗.中华实用西医杂志,2003,16(3):344-344.
9Mochizuki S,Shimizu M,Taniguchi l,et al. JIKEI HEART Study-amorbi - mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease[J]. Cardiovasc Drugs Tner, 2004, 18:305 - 309.
